5325232025-04-012025-06-305325232025-06-305325232025-04-012025-06-30in-capmkt:OtherExpenses1Member5325232025-04-012025-06-30in-capmkt:OtherExpenses2Member5325232025-04-012025-06-30in-capmkt:ReportableSegments1Member5325232025-04-012025-06-30in-capmkt:ReportableSegments2Member5325232025-04-012025-06-30in-capmkt:ReportableSegments3Member5325232025-04-012025-06-30in-capmkt:ReportableSegments1Member5325232025-04-012025-06-30in-capmkt:ReportableSegments2Member5325232025-04-012025-06-30in-capmkt:ReportableSegments3Member5325232025-04-012025-06-30in-capmkt:ReportableSegments1Member5325232025-06-30in-capmkt:ReportableSegments1Member5325232025-04-012025-06-30in-capmkt:ReportableSegments2Member5325232025-06-30in-capmkt:ReportableSegments2Member5325232025-04-012025-06-30in-capmkt:ReportableSegments3Member5325232025-06-30in-capmkt:ReportableSegments3Member5325232025-04-012025-06-30in-capmkt:ReportableSegments1Member5325232025-06-30in-capmkt:ReportableSegments1Member5325232025-04-012025-06-30in-capmkt:ReportableSegments2Member5325232025-06-30in-capmkt:ReportableSegments2Member5325232025-04-012025-06-30in-capmkt:ReportableSegments3Member5325232025-06-30in-capmkt:ReportableSegments3Member5325232025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5325232025-04-012025-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

532523

BIOCON

NOTLISTED

INE376G01013

BIOCON LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-08-07

2025-07-08

INR

Millions

Quarterly

First quarter

Multi segment

2025-08-07

18:15:00

2025-08-07

19:10:00

Not applicable

2025-04-01

2025-06-30

Unaudited

Consolidated

39419000000

797000000

40216000000

12240000000

8371000000

-6560000000

8331000000

2767000000

4550000000

9548000000

39247000000

969000000

667000000

-590000000

77000000

892000000

-2055000000

-1163000000

314000000

578000000

-1735000000

572000000

6685000000

0.26

Notes: 1. The unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘’Syngene’’) ii. Biocon Biologics Limited (“BBL”) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics UK Limited ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited xxi. Syngene Scientific Solutions Limited xxii. Biosimilar Collaborations Ireland Limited xxiii. Biosimilars Newco Limited xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L. xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of the above proceeds, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) of face value of Rs. 1,00,00,000 issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million. 5. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- with record date of July 4, 2025. The proposed dividend is subject to the approval of the shareholders of the Company in its Annual General Meeting. 6. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the quarter ended June 30, 2024 and year ended March 31, 2025. 7. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the year ended March 31, 2025. 8. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. 9. During the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) has acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). The transaction has been accounted for as an 'asset acquisition' under Ind AS 103. The costs incurred till March 31, 2025 eligible for capitalization are being accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter ended 30 June 2025, additional pre-operating cost of Rs. 55 million eligible for capitalisation has been accumulated under capital work in progress. 10. Exceptional items: a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 365 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 79 million and Rs. 147 million is included within tax expense for the respective period/ year. c. During the quarter ended June 30, 2024 and year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. d. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. e. During the year ended March 31, 2024, one of the subsidiaries of Biocon Biologics Limited (“BBL”) had received Rs. 18,269 million towards working capital under the existing arrangements. BBL had recorded these receivables at fair value of Rs. 10,219 million having regard to the timing and probability of recovery. During the year ended March 31, 2025, BBL settled Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. f. During the year and quarter ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. 11. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto third quarter of the relevant financial year, which were subject to limited review. For and on behalf of the Board of Directors of Biocon Limited Bangalore, Kiran Mazumdar-Shaw August 07, 2025 Executive Chairperson DIN: 00347229

Other Expenses

9894000000

Recovery of cost from co-development partners (net)

-346000000

Generics

6965000000

Biosimilars

24578000000

CRDMO

8745000000

40288000000

869000000

39419000000

Generics

-670000000

Biosimilars

960000000

CRDMO

1013000000

1303000000

334000000

969000000

Generics

79533000000

Biosimilars

447112000000

CRDMO

66747000000

593392000000

20549000000

613941000000

Generics

29318000000

Biosimilars

224602000000

CRDMO

18282000000

272202000000

21764000000

293966000000

Contract Research, Development, and Manufacturing Organisation (CRDMO) formerly referred to as 'Research Services', in line with Company's current business model. Notes: 1. The unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 in respect of Biocon Limited (‘the Company’) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 07, 2025. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. 2. These financial results have been prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include the financial results of the Company and its subsidiaries as follows: i. Syngene International Limited (‘’Syngene’’) ii. Biocon Biologics Limited (“BBL”) iii. Biocon Pharma Limited (“BPL”) iv. Biocon Academy v. Biocon SA vi. Biocon SDN. BHD vii. Biocon FZ LLC viii. Biocon Biologics UK Limited ix. Biocon Pharma Inc. x. Biocon Biologics Healthcare Malaysia SDN. BHD xi. Biocon Pharma Ireland Limited xii. Biocon Pharma UK Limited xiii. Biocon Biosphere Limited xiv. Biocon Biologics Inc. xv. Biocon Biologics Do Brasil Ltda xvi. Biocon Biologics FZ-LLC xvii. Biocon Pharma Malta Limited xviii. Biocon Pharma Malta I Limited xix. Syngene USA Inc. xx. Syngene Manufacturing Solutions Limited xxi. Syngene Scientific Solutions Limited xxii. Biosimilar Collaborations Ireland Limited xxiii. Biosimilars Newco Limited xxiv. Biocon Biologics Canada Inc. xxv. Biocon Biologics Germany GmbH xxvi. Biocon Biologics France S.A.S xxvii. Biocon Biologics Spain, S.L. xxviii. Biocon Biologics Switzerland AG xxix. Biocon Biologics Belgium BV xxx. Biocon Biologics Finland OY xxxi. Biocon Generics Inc. xxxii. Biocon Biologics Morocco S.A.R.L.A.U xxxiii. Biocon Biologics Greece SINGLE MEMBER P.C xxxiv. Biocon Biologics South Africa (PTY) Ltd xxxv. Biocon Biologics (Thailand) Co. Ltd xxxvi. Biocon Biologics Philippines Inc xxxvii. Biocon Biologics Italy S.R.L xxxviii. Biocon Biologics Croatia LLC xxxix. Biocon Biologics Global PLC Biocon Limited and its subsidiaries are collectively referred to as ‘the Group’. In addition to the above, the consolidated financial results also include the financial results in respect of Biocon India Limited Employee Welfare Trust, Biocon Limited Employees Welfare Trust, Biocon Biologics Employees Welfare Trust and Syngene Employees Welfare Trust. The Company has also accounted for its share of interest in the joint venture i.e. NeoBiocon FZ-LLC (‘JV’) and share of investment in the associate i.e. Iatrica Inc., under the equity method. 4. During the quarter ended June 30, 2025, the Company raised funds by way of allotment of 136,363,635 Equity Shares of face value Rs. 5 each at a price of Rs. 330 per Equity Share under ‘Qualified Institutional Placement’ for an aggregate amount of Rs. 45,000 million, to meet certain financial commitments and / or debt obligations of the Company and its subsidiary, BBL and/ or for other purposes as mentioned in the Placement Document (‘PD’). Out of the above proceeds, the Company acquired 1,125 outstanding Optionally Convertible Debentures (‘OCDs’) of face value of Rs. 1,00,00,000 issued by BBL from Goldman Sachs India AIF Scheme- 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme – 2 for an aggregate value of Rs. 16,980 million. 5. On May 08, 2025, the Board of Directors of the Company recommended a final dividend of Rs. 0.50 per equity share of Rs. 5/- with record date of July 4, 2025. The proposed dividend is subject to the approval of the shareholders of the Company in its Annual General Meeting. 6. In April 2024, BBL sold to Eris Lifesciences (‘Eris’) its business in relation to Metabolics, Oncology, and Critical Care products in India for a consideration of Rs. 12,420 million. Further, BBL signed a 10 year supply agreement with Eris. This resulted in a gain of Rs. 10,573 million after taking into account working capital and expenses incurred towards commercial collaboration and the same is disclosed under ‘’Other income” in the consolidated financial results for the quarter ended June 30, 2024 and year ended March 31, 2025. 7. Pursuant to amendment in The Finance Act, 2024, resulting in withdrawal of indexation benefit on Long-Term Capital Gain, the Company has written off Deferred Tax Asset created towards indexation benefit on Land amounting to Rs. 199 million. This is recorded under ‘Tax expense’ in the standalone and consolidated financial results for the year ended March 31, 2025. 8. The Group considers estimated shelf life of products, planned product discontinuances, price changes, ageing of inventory and introduction of competitive new products, to the extent each of these factors impact the Group’s business and markets, in determining the provision for slow moving, obsolete and other non-saleable inventory. Pursuant to the take-over of the Viatris's biosimilar business and completion of first anniversary since the exit from the transition service agreement, BBL re-assessed the provision for inventory of finished goods, raw material and semi-finished goods. This assessment resulted into a release of provision of Rs. 650 million in the year ended March 31, 2025 and the credit has been accounted for as a change in estimate within ‘Changes in inventories of traded goods, finished goods and work-in-progress’ and ‘Cost of materials consumed’ in the consolidated financial results. 9. During the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of Syngene) has acquired biologics site in the USA fitted with multiple monoclonal antibody (mAbs) manufacturing lines from Emergent Manufacturing Operations Baltimore, LLC (a subsidiary of Emergent BioSolutions Inc.). The transaction has been accounted for as an 'asset acquisition' under Ind AS 103. The costs incurred till March 31, 2025 eligible for capitalization are being accumulated as Capital Work In Progress amounting to Rs. 2,981 million. An amount of Rs. 311 million has been capitalized as Land. These amounts include pre-transaction costs of Rs. 101 million. During the quarter ended 30 June 2025, additional pre-operating cost of Rs. 55 million eligible for capitalisation has been accumulated under capital work in progress. 10. Exceptional items: a. During the year ended March 31, 2025, the Company sold 8,000,000 equity shares of Rs. 10 each of Syngene in the open market. The gain arising from sale of aforesaid equity shares amounting to Rs. 6,075 million has been recorded as an exceptional item in the standalone financial results. Consequent tax impact of Rs. 261 million is included within tax expense for the year. The sale proceeds arising from such sale of aforesaid equity shares net of amount transferred to Non-Controlling Interest account, has been accounted in other equity in the consolidated financial results since there is no loss of control. b. During the year ended March 31, 2024, one of the subsidiaries of BBL recorded provision for inventory for a product due to its low demand and consequentially lower probability of liquidation under the head ‘Exceptional Item’. Subsequently, during the quarter and year ended March 31, 2025, BBL liquidated such inventory amounting to Rs. 365 million and Rs. 885 million, respectively. Hence, the related provision has been reversed and reflected as an exceptional item in the consolidated financial results. Consequential tax impact of Rs. 79 million and Rs. 147 million is included within tax expense for the respective period/ year. c. During the quarter ended June 30, 2024 and year ended March 31, 2025, Syngene received its final claim of Rs. 320 million from the insurance company for the loss of fixed assets in fire incident on December 12, 2016. d. BBL had written off the unamortized portion of debt raise cost amounting to Rs. 1,216 million pertaining to acquisition debt pursuant to pre-payment of such debt. This has been recorded as an expense in the consolidated statement of profit and loss for the year ended March 31, 2025. Consequent tax impact of Rs. 304 million is included within tax expense for the year. e. During the year ended March 31, 2024, one of the subsidiaries of Biocon Biologics Limited (“BBL”) had received Rs. 18,269 million towards working capital under the existing arrangements. BBL had recorded these receivables at fair value of Rs. 10,219 million having regard to the timing and probability of recovery. During the year ended March 31, 2025, BBL settled Rs. 2,518 million towards working capital under the existing arrangements, which was recorded at fair value of Rs. 1,382 million. The resulting difference of Rs. 1,136 million is recorded as a gain in the consolidated financial results. Consequential tax impact of Rs. 284 million is included within tax expense. f. During the year and quarter ended March 31, 2025, one of the subsidiary of Biocon Pharma Limited (‘BPL’), pursuant to the uncertainty in commercialization of product in certain territories, recorded an impairment of the carrying value of the intangible asset amounting to Rs. 86 million. g. During the year ended March 31, 2025, the Group invested Rs. 75 million in the equity shares issued by Indian Foundation for Quality Management ('IFQM') a Company incorporated under section 8 of the Companies Act, 2013. As at March 31, 2025, the Group has fair valued such investment and has recorded fair value charge of Rs. 75 million. 11. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures upto third quarter of the relevant financial year, which were subject to limited review. For and on behalf of the Board of Directors of Biocon Limited Bangalore, Kiran Mazumdar-Shaw August 07, 2025 Executive Chairperson DIN: 00347229

Items that will not be reclassified to profit or loss

-1838000000

-95000000

Items that will be reclassified to profit or loss

-586000000

-274000000

-2055000000